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AbstrAct
MYC oncoproteins deliver a potent oncogenic stimulus in several human cancers, 
making them major targets for drug development, but efforts to deliver clinically 
practical therapeutics have not yet been realized. In childhood cancer, aberrant 
expression of MYC and MYCN genes delineates a group of aggressive tumours 
responsible for a major proportion of pediatric cancer deaths. We designed a 
chemical-genetic screen that identifies compounds capable of enhancing proteasomal 
elimination of MYCN oncoprotein. We isolated several classes of compound that 
selectively kill MYCN expressing cells and we focus on inhibitors of PI3K/mTOR 
pathway in this study. We show that PI3K/mTOR inhibitors selectively killed MYCN-
expressing neuroblastoma tumor cells, and induced significant apoptosis of transgenic 
MYCN-driven neuroblastoma tumors concomitant with elimination of MYCN protein 
in vivo. Mechanistically, the ability of these compounds to degrade MYCN requires 
complete blockade of mTOR but not PI3 kinase activity and we highlight NVP-BEZ235 
as a PI3K/mTOR inhibitor with an ideal activity profile. These data establish that 
MYCN expression is a marker indicative of likely clinical sensitivity to mTOR inhibition, 
and provide a rationale for the selection of clinical candidate MYCN-destabilizers likely 
to be useful for the treatment of MYCN-driven cancers.
INtrODUctION
Aberrant expression of the transcription factors 
MYC and MYCN (a MYC homologue with expression 
limited to undifferentiated neurons) delivers a potent 
oncogenic stimulus in cancer, making MYC oncoproteins 
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attractive targets for pharmacologic inhibition [1-7]. In 
pediatric cancer, expression of MYCN is selectively 
confined to tumor tissue in medulloblastoma [8], 
neuroblastoma [1, 2], rhabdomyosarcoma [7], and a subset 
of retinoblastoma [9], four common solid tumors that 
together account for a substantial proportion of relapsed 
cancer deaths in children. Pharmacologic inhibition 
of MYCN oncoprotein is therefore of great interest in 
pediatric cancer; however, direct targeting of MYCN, or 
MYC oncoproteins in general, has not yet delivered viable 
therapeutics to the clinic. 
A substantial body of work suggests two approaches 
by which MYC proteins could be therapeutically targeted. 
First, synthetic lethal interactions are generated by 
persistent overexpression of MYC in cancer cells and 
impart therapeutic sensitivity [10-16]. Genetic screens 
utilizing RNA-interference have identified relationships 
between expression of MYC and a defined set of 
additional genes, suppression of which induces lethality 
restricted to cells with MYC or MYCN expression (CDK1, 
CDK2, AURKA, AURKB, CHK1) [10-12, 17-23]. Second, 
MYC-family oncoproteins are oncogenically stabilized by 
altered phosphorylation within an N-terminal conserved 
phosphodegron domain (CPD) [14, 24-26]. Binding to 
the CPD is a function of the ubiquitin ligases (FBW7, 
HUWE1) and is required for initiation of proteasomal 
degradation [4, 24, 27]. Phosphorylation of conserved T58 
and S62 residues within the CPD is regulated by CDK1 
(a MAPK target), and by the PI3K/AKT-regulated targets 
GSK3β and mTOR, respectively [28-30]. Cancers defined 
by mutations in FBW7 (which disrupt the association of 
FBW7 with the CPD-client protein) are characterized 
by elevated levels of the CPD-client oncoproteins MYC 
[31], c-Jun [32], cyclin E [33] and NOTCH [34]. Aberrant 
stimulation of MAPK or PI3K pathways also contributes 
to oncogenic stabilization of MYCN in certain cancers. In 
neuroblastoma, enhanced PI3K signaling correlates with 
poor prognosis and aggressive tumor biology [35, 36]. 
Previous work established that in cancer cell lines, excess 
PI3K pathway signaling modulates the AKT-regulated 
targets GSK3β and mTOR, extending the half-life of 
MYC and outlining a potential pharmacologic approach 
for targeting MYC stability [28-30, 34, 37]. 
To our knowledge, a chemical-genetic screen that 
addresses these two mechanisms, corroborating previous 
synthetic lethality studies of MYC oncogene expression or 
providing the targets for MYC oncoprotein destabilization, 
has not been reported. With this in mind, we designed a 
cell-based screen utilizing an isogenically derived set of 
neuroblastoma cells with either high-level expression of 
wild-type MYCN or with genetically modified, stabilized 
MYCN (lacking the CPD target phosphorylation residues, 
T58 and S62). Potent compounds that have mechanistic 
activity in cells expressing wild-type, but not CPD 
mutated, MYCN protein should antagonize oncogenic 
stabilization of MYCN protein and target synthetic lethal 
relationships associated with MYCN expression. We 
outline a strategy to identify compounds that specifically 
target wild-type MYCN protein and present a chemical 
screen that identifies small-molecules with the ability 
to indirectly pharmacologically target MYCN (and 
potentially MYC) protein. Compounds inhibiting several 
genetic pathways were identified in the screen and in this 
study we characterize small-molecule inhibitors of the 
PI3K/mTOR pathway. We show that inhibitors of PI3K/
mTOR, or mTOR kinase activity alone, exhibit selective 
activity against cells that express high-levels of MYCN 
protein. NVP-BEZ235, a potent inhibitor of both PI3K 
and mTOR-kinases, which is already in clinical trials for 
PI3K pathway-mutated adult cancers, eliminated intra-
tumoral MYCN and induced regression of MYCN-driven 
transgenic neuroblastoma tumors in vivo. 
Overall our observations raise the exciting 
possibility that a group of poor-outcome pediatric cancers 
could be effectively targeted through their expression of a 
tumor-specific oncoprotein, using available and clinically 
tested therapeutics.
rEsULts
screen for small-molecules that target MYcN 
oncoprotein stability
We designed a focused chemical-genetic screen 
that would identify small-molecules with a mechanistic 
ability to target cells expressing high-levels of wild-
type MYCN. Expression constructs encoding FLAG-
tagged wild type or stabilized (CPD-mutated) MYCN 
proteins were transfected into human neuroblastoma 
cells lacking endogenous MYCN expression. Equivalent 
levels of MYCN expression were achieved in SHEP cells 
expressing wild-type MYCN (SHEP WT) in comparison 
to a range of established, tumor-derived neuroblastoma 
cell lines known to express high-levels of MYCN (Figure 
S1A). However, elevated levels of MYCN expression 
were observed in SHEP cells expressing mutated MYCN 
(SHEP T58, SHEP S62 and SHEP T58/S62) in comparison 
with both SHEP WT and established neuroblastoma cell 
lines - consistent with the stabilization of CPD-mutated 
MYCN (Figure S1A, B). SHEP cells expressing both wild 
type and mutant MYCN proteins all exhibited significantly 
increased cellular proliferation in comparison to parental 
SHEP cells but not to each other (Figure S1C). 
To establish the MYCN dependency of both the 
native neuroblastoma cell line Kelly and the SHEP WT 
and SHEP T58/S62 mutant MYCN lines, we abrogated 
MYCN expression via siRNA-mediated knockdown. 
Inhibition of MYCN in the Kelly cell line induced cell 
death as measured by trypan blue exclusion (Figure 
S1D) and similarly, although to a lesser extent, MYCN 
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cell viability was diminished with siRNA treatment in 
both SHEP WT and SHEP T58/S62 neuroblastoma cell 
lines (Figure S1E, F), confirming that exogenous MYCN 
expression is responsible for the increased proliferation 
observed in SHEP WT and SHEP T58/S62 cells. 
Using cellular proliferation as an endpoint, we 
selected for compounds with enhanced activity against 
SHEP WT cells compared to SHEP T58/S62 cells 
expressing stabilized MYCN. We reasoned that this 
selection would enrich for compounds with mechanistic 
activity against MYCN but exclude compounds with 
generic activity related to inhibition of cell proliferation 
rather than MYCN stability. The screen was performed 
using an in-house kinase inhibitor library of 228 
compounds at low, intermediate and high concentrations 
(40nM, 200nM and 1μM) to identify compounds that 
exhibit on-target effects whilst excluding the possibility of 
off-target effects exerted by kinase inhibitors at excessive 
concentrations (>1μM). The top 25 ranked inhibitors that 
showed selective inhibition of SHEP WT cells included 
inhibitors of JAK/STAT pathway, receptor tyrosine kinases 
(PDGFR), PI3K pathway (PI3K, AKT and mTOR), and 
cell cycle checkpoints (AURKA, AURKB, CDK, PLK, 
WEE1 and CHK1) (Figure 1A). 
The specificity of 17 of the inhibitors in this list 
has been profiled against a panel of 300 protein kinases 
[38]. Several demonstrate off-target activity, with 6 (JAK 
Inhibitor I, SU6656, SU11652, JAK3 Inhibitor VI, PKR 
Inhibitor and Aurora Kinase/Cdk Inhibitor) inhibiting >25 
kinases by >75%, and a further 3 (PDGF RTK Inhibitor, 
PDGF Receptor Tyrosine Kinase Inhibitor IV and Cdk2 
Inhibitor IV-NU6140) inhibiting >5 kinases. Of these, 5 
had activity against both Aurora A and B (Jak inhibitor 
I, SU6656, PDGF RTK inhibitor, PKR inhibitor, Aurora 
kinase/CDK inhibitor), Aurora A (Cdk2 Inhibitor IV-
NU6140) or Aurora B (Jak3 VI inhibitor). The JAK 
inhibitor I also inhibited CHK1 and PLK1, CHK1 was 
also inhibited by SU11652 and the JAK3 VI inhibitor, 
and CDK1 was inhibited by the JAK3 VI inhibitor, PKR 
inhibitor and the Aurora Kinase/Cdk Inhibitor. The off-
target and on-target activity of several of these inhibitors 
included AURA [12], AURB [39], CDK1 [10] and CHK1 
[17] that have been reported to regulate MYCN stability 
or exhibit a synthetic lethal interaction with MYCN 
dependence. Our focused screen therefore appears to have 
strong predictive ability to identify compounds that are 
selective inhibitors of cells expressing MYCN protein. 
This chemically driven screen appears to validate previous 
RNAi driven loss-of-function studies, which highlighted 
the potential for pharmacologic targeting of synthetic 
lethal interactions in MYCN expressing cancers. 
PI3K pathway inhibitors selectively target cells 
with MYcN expression
Potent and selective inhibitors of PI3K and/or 
mTOR pathways have entered clinical trials in both adult 
and pediatric cancers, and could be valuable agents for 
treatment of childhood cancers [40, 41]. The fact that PI-
103, a potent and highly specific small-molecule inhibitor 
of class I PI3K and mTOR [42-44] preferentially targeted 
MYCN-expressing cells in our screen was of particular 
interest to us. Preliminary studies demonstrated that 
LY294002, a first-generation, weak inhibitor of PI3K 
pathway that has off-target liabilities [45], destabilized 
MYCN and could partially inhibit the growth of MYCN-
driven neuroblastoma tumors [46] but its use was limited 
by the off-target toxicity profile of LY294002, which 
restricted in vivo dosing. Given the activity of PI-103 (a 
more potent and selective inhibitor of PI3K signaling than 
LY294002) in our focused screen, and the availability of 
additional potent and selective PI3K inhibitors for clinical 
use, we focused on the role of PI3K/mTOR signaling in 
MYCN stability (Table S1).
We first re-confirmed our initial observation that 
the proliferation of SHEP WT cells was preferentially 
inhibited by PI-103 treatment using a trypan blue exclusion 
assay (Figure 1B). SHEP WT cells exhibited a 4.8-fold 
and 2.9-fold increased sensitivity to PI-103 compared to 
the parent SHEP cells or SHEP T58/S62 respectively. This 
differential sensitivity pattern was reproduced with NVP-
BEZ235 [47], an imidazo-[4,5-c]-quinoline derivative 
PI3K and mTOR inhibitor (7.1 and 4.7-fold respectively), 
and also with Torin1 [48], an ATP-competitive mTOR-
kinase (mTORC1 and mTORC2) inhibitor lacking PI3K 
inhibition, and to a lesser degree with ZSTK474 [49], a 
pan class I PI3K inhibitor that has poor activity against 
mTOR (3.8 and 3.2-fold respectively). In addition, the 
native neuroblastoma Kelly cells also exhibited a similar 
sensitivity profile as the SHEP WT cells (Figure 1B). 
These results show a clear trend in drug sensitivity where 
inhibition of cell proliferation aligns with the degree of 
MYCN amplification and protein expression. Our findings 
were reinforced both in an independent sulforhodamine B 
(SRB) assay of cell proliferation, and also in a larger cell 
panel that included four primary neuroblastoma cell lines 
with MYCN gene amplification, three cell lines with diploid 
MYCN and four engineered SHEP cell lines expressing 
mutated or wild-type exogenous MYCN protein (Table 
S2). Furthermore, TGX221, an isoform-selective p110β-
selective PI3K inhibitor and rapamycin, a non-ATP site 
and incomplete inhibitor of mTOR (mTORC1-specific), 
showed relatively non-specific activity against this panel. 
The activity of NVP-BEZ235 and Torin1 against Kelly 
and three additional MYCN-amplified neuroblastoma cell 
lines correlated with induction of apoptosis in the Kelly 
cell line by two independent assays (Figure 1D, 1E). 
This data suggests that within the spectrum of available 
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Figure 1: Identification of PI3K/mTOR inhibitors that selectively target MYCN-expressing tumor cells. A. SHEP WT 
and SHEP T58/S62 cells were treated at a concentration of 40, 200 and 1000nM for 96 h with a panel of 228 kinase inhibitors exhibiting 
a range of kinome inhibitory properties. Cell viability was determined using CellTiter-blue reagent. The Z factor for all assay plates was 
>0.5. The data are displayed as a ratio of SHEP T58/S62:SHEP WT, increased red indicates increased activity in SHEP WT compared 
to SHEP T58/S62 cells. B. Cell viability as determined by trypan blue exclusion method in Kelly, SHEP, SHEP WT and SHEP T58/S62 
neuroblastoma cells. Cells were treated for 72 h with PI-103, NVP-BEZ235, Torin1 or ZSTK474. Mean GI50 and standard error from three 
independent assays are shown. C. Representative log curves of Kelly cells treated for 72 h with, NVP-BEZ235, Torin1 or ZSTK474. Values 
represent the averages of three independent assays. Error bars; standard deviation. D. Induction of apoptosis 24 h post treatment with 
DMSO, NVP-BEZ235, ZSTK474, Torin1 or Staurosporine (as a positive control) in Kelly neuroblastoma cells as measured by Caspase-
Glo 3/7 cleavage assay. Values are fold activation of caspase activity normalised to DMSO control and are averages of three assays. 
Error bars; standard deviation. E. Induction of apoptosis and necrosis by NVP-BEZ235. Kelly cells were treated with NVP-BEZ235 or 
Staurosporine (STAR) as a positive inducer of apoptosis and cell apoptosis and necrosis assessed via Cell Death ELISA (Roche™) 24 h 
post treatment. (Apoptosis; red bars and necrosis; black bars). Values are fold induction of histone-associated DNA fragments normalized to 
DMSO control and are averages of three assays. Error bars; standard deviation. F. Growth inhibitory (GI50s) values carried out at 72 h using 
the SRB assay of a panel of adult cancer cell lines carrying PIK3CA/PTEN mutations compared with pediatric cancer cell lines containing 
a spectrum of MYCC/N gene copy number or mutated MYCN. See also Figure 1B and Table S2.
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PI3K/mTOR pathway-active compounds, selective 
mTOR kinase inhibitors or dual inhibitors of PI3K and 
mTOR kinases are most likely to exhibit potent activity in 
neuroblastoma cells that express MYCN. 
Expression of MYcN selectively sensitizes cells to 
PI3K/mTOR inhibition
The enhanced sensitivity of MYCN overexpressing 
Figure 2: Inhibition of PI3K/mTOR signaling destabilizes MYCN. A.-D. Mesoscale Discovery (MSD) analysis of PI3K/mTOR 
signaling components AKTSER473,GSK3βSER9, pP70S6KTHR389 and RPS6SER240/244 SHEP WT and SHEP T58/S62 cell lysates were collected 3 
h after treatment with NVP-BEZ235 and analysed for inhibitory effects on the phosphorylation of AKTSER473, GSK3βSER9, RPS6SER240/244 and 
pP70S6KTHR389. Analysis was performed in triplicate using the MesoScale Discovery assay. Data are expressed as percent of control and 
values are shown as mean + SEM. E.-G. Immunoblotting analyses of time and concentration dependent effects of NVP-BEZ235, ZSTK474 
and Torin1 treatment on MYCN stability and PI3K/mTOR biomarker AKTSER473, GSK3βSER9, 4EPB1THR37/46 modulation. Kelly cells were 
seeded and 24 h later treated with DMSO only (V), DMSO and IGF1 (V+I) or with NVP-BEZ235, Torin1 or ZSTK474 for the indicated time 
and concentrations. All inhibitor treated cells were stimulated with IGF1 (50ng/ml) 30 minutes prior to harvesting. AKTSER473, GSK3βSER9, 
4EPB1THR37/46 MYCNTHR58 and total AKT, GSK3β, 4EPB1 and MYCN were assessed via western blotting and GAPDH used as a loading 
control. H. Immunoblotting analyses of concentration dependent effects of NVP-BEZ235, ZSTK474 and Torin1 treatment on MYCN 
stability and PI3K/mTOR biomarker AKTSER473, GSK3βSER9 and 4EPB1THR37/46 modulation. IMR5 (Left panel) and SKN-Be2C (Right panel) 
neuroblastoma cells were seeded and 24 h later treated with DMSO only (V), DMSO and IGF1 (V+I) or with NVP-BEZ235, Torin1 or 
ZSTK474 at the indicated doses. All inhibitor treated cells were stimulated with IGF1 (50ng/ml) 30 minutes prior to harvesting. AKTSER473, 
GSK3βSER9, 4EPB1THR37/46 MYCNTHR58 and total AKT, GSK3β, 4EPB1 and MYCN were assessed via western blotting and GAPDH used as 
a loading control.
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neuroblastoma cell lines to PI3K/mTOR inhibition is 
somewhat surprising, since these cells lack intrinsic 
mutations in the PI3K pathway members PTEN or 
PIK3CA. These mutations prime cells for response to 
PI3K pathway inhibitors and therefore provided the 
rationale for the initial use of these agents in clinical 
trials [50-52]. To examine whether MYCN expressing 
neuroblastoma cells exhibit similar sensitivity to cells 
harboring intrinsic PI3K pathway mutations we used 
NVP-BEZ235 to treat a range of adult cancer cell lines 
(PTEN or PIK3CA mutant, with varying expression levels 
of MYC [53-58]), together with pediatric cell lines (wild-
type for PTEN and PIK3CA) but with varying expression 
levels of either MYC or MYCN (Figure 1F). We found 
that cell lines harboring no/intermediate expression of 
MYCN or with stabilized MYCN were significantly 
less sensitive to NVP-BEZ235 compared to both MYC 
and MYCN-amplified cell lines (P < 0.0001). Therefore, 
expression of MYCN is a marker of sensitivity to NVP-
BEZ235 treatment in pediatric cell lines and confers 
sensitivity equivalent to that of adult cell lines mutated in 
PTEN or PIK3CA. Taken together, the implication is that 
expression of MYCN is a marker of sensitivity to PI3K/
mTOR pathway inhibition in neuroblastoma cells.
Having identified selective sensitivity of MYCN-
dependent cells to treatment with PI3K/mTOR inhibitors, 
we examined whether this could be explained by an 
intrinsic difference in PI3K pathway activation in these 
cells. We used an electro-chemiluminescent assay 
that quantitates PI3K/mTOR signaling intermediates 
(AKTSER473, GSK3βSER9, p70S6KTHR389 and RPS6SER240/244) 
to compare PI3K/mTOR pathway inhibition in SHEP 
cells with exogenous expression of either MYCN WT or 
MYCN T58/S62 protein mutated within the CPD domain. 
NVP-BEZ235 caused potent blockade of PI3K and mTOR 
pathways in both SHEP WT and SHEP T58/S62 cell 
lines (Figure 2A-2D). Therefore the variance in viability 
between SHEP WT and SHEP T58/S62 cells following 
treatment with NVP-BEZ235 is unlikely to be due to 
differential inhibition of PI3K/mTOR pathway activity.
Degradation of MYcN protein correlates with 
blockade of mtOr, not PI3K activity
We next sought to establish whether MYCN-
selective inhibition observed in cellular assays correlates 
with elimination of MYCN protein, and if so, which 
component of PI3K pathway blockade is required for 
efficacy. To establish a time- and concentration-dependent 
biomarker response in a native neuroblastoma cell line we 
treated Kelly (MYCN-amplified, high MYCN protein) cells 
with NVP-BEZ235 for 1, 3, 6 and 12 h. Treatment led to 
a rapid (3 h) and sustained (12 h) elimination of MYCN 
protein by NVP-BEZ235 and Torin1 accompanied by a 
decrease in phosphorylation of 4EBP1THR37/46 (regulated by 
mTORC1) and AKTSER473 (regulated by mTORC2) (Figure 
2E, 2F). Compared to NVP-BE235 and Torin1, there was 
no significant degradation of MYCN with ZSTK474 
treatment, despite evidence of PI3K pathway inhibition 
indicated by a decrease in AKTSER473 and GSK3βSER9 
phosphorylation (Figure 2G). We confirmed these 
observations in two other MYCN-amplified neuroblastoma 
cell lines, IMR5 and SKN-Be2C, which showed similar 
patterns in sensitivity and biomarker modulation with all 
three drug treatments (Figure 2H). Furthermore, we treated 
the Kelly cell line at 2, 5 and 10μM with ZSTK474, 
which at higher concentrations can be a weak inhibitor of 
mTOR [59], and observed destabilization of MYCN, but 
only where mTOR activity was modulated (as measured 
through inhibition of both 4EBP1THR37/46 and RPS6SER240/244 
(Figure 3A). Additionally, following cycloheximide 
treatment, the half-life of MYCN was shortened by NVP-
BEZ235 and Torin1 but not by ZSTK474 (Figure 3B). 
Taken together, these data imply that the ability of PI3K/
mTOR pathway inhibitors to eliminate MYCN protein 
correlates with effective targeting of both mTORC1 and 
mTORC2 activity. 
blockade of mtOr stimulates proteasomal 
degradation of MYcN protein
We next assessed whether the ability of mTOR-
kinase inhibitors to eliminate MYCN exhibited 
evidence of dependence on the ubiquitin-ligase, 
proteasome degradation pathway. Treatment with the 
proteasome inhibitor MG132 resulted in accumulation of 
phosphorylated MYCN and reversed the ability of NVP-
BEZ235 to degrade MYCN protein (Figure 3C). NVP-
BEZ235 efficiently and rapidly eliminated exogenously 
expressed MYCN-WT protein in SHEP WT cells (Figure 
3D), an effect that was completely blocked by mutation 
of the CPD-domain T58 and S62 phosphorylation sites, 
despite evidence of excellent mTOR/PI3K pathway 
inhibition (Figure 3E). This suggests that the ability of 
PI3K/mTOR pathway inhibitors to eliminate MYCN is 
mediated by phosphorylation of the N-terminal FBW7 
target CPD domain, since mutation of phosphorylation 
sites within the CPD completely reverses the ability of 
these drugs to degrade MYCN (compare Figure 3D, 3E). 
We therefore concluded that the elimination of MYCN 
protein caused by mTOR/PI3K pathway blockade is at 
least in part mediated through phosphorylation of MYCN 
T58/S62 phospho-residues.
PI3K activity is not required for maintenance of 
cellular MYcN levels
Our results indicate that PI3K inhibitors with weak 
activity against mTOR fail to target MYCN protein, 
implying that activity of the PI3K complex may not 
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Figure 3: Inhibition of PI3K/mTOR signaling destabilizes MYCN. A. Depletion of MYCN following treatment with high 
concentrations of ZSTK474, as measured by western blot analysis of AKTSER473, GSK3βSER9, 4EPB1THR37/46, RPS6SER240/244 and MYCN. Kelly 
cells were treated with DMSO (V), DMSO and IGF1 (V+I) or with ZSTK474, at the indicated concentration. All treated cells were stimulated 
with IGF1 (50ng/ml) 30 minutes prior to harvesting. Total AKT, RPS6 and 4EPB1 were used as controls for each corresponding phospho-
specific antibody and GAPDH used as a loading control. B. Treatment of Kelly neuroblastoma cells with 1XGI50 concentration of NVP-
BEZ235, Torin1 or ZSTK474 shortens the half-life of MYCN. Kelly neuroblastoma cells were treated with DMSO, NVP-BEZ235, Torin1 
or ZSTK474 for 2 h before the addition of cycloheximide (5µM) for 1 h to block translation of MYCN. Total MYCN protein expression was 
assessed by western blotting, and GAPDH used as a loading control. C. Hyper-phosphorylation of T58/S62 phosphoresidues of MYCN is 
driven by PI3K/mTOR inhibition. Kelly neuroblastoma cells were treated with DMSO (V), DMSO and the proteasomal inhibitor MG-132, 
or with NVP-BEZ235 in the presence of MG132 for 3 h. Total, S62 and T58 pools of MYCN protein were assessed via western blot and 
GAPDH used as a loading control. D. Concentration dependent effects of NVP-BEZ235, Torin1 and ZSTK474 treatment on PI3K/mTOR 
pathway biomarkers AKTSER473, GSK3βSER9, 4EPB1THR37/46and MYCN stability in SHEP WT and (E) SHEP T58/S62 neuroblastoma cells. 
SHEP WT and SHEP T58/S62 cells were treated with DMSO (V), DMSO and IGF1 (V+I) or with NVP-BEZ235, Torin1 and ZSTK474 
for 3 h. All treated cells were stimulated with IGF1 (50ng/ml) 30 minutes prior to harvesting. Total AKT, GSK3β, and 4EPB1 were used as 
controls for each corresponding phospho-specific antibody and GAPDH was used as a loading control. 
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play a major role in stabilization of MYCN protein in 
neuroblastoma cells. To mechanistically address this 
possibility, we silenced p110α-PI3K expression in 
short- and long-term assays using siRNA and shRNA, 
respectively. Elimination of p110α activity blocked 
phosphorylation of AKT but failed to reduce cellular 
MYCN protein levels (Figure 4A, 4B) or alter cell 
proliferation (Figure 4C). In addition, the ability of 
NVP-BEZ235 to stimulate MYCN degradation in these 
cells (immunoblot Figure 4D, 4E) or their sensitivity to 
treatment with NVP-BEZ235 (GI50, as measured by 72 
h SRB cytotoxicity assay, Figure 4F) was not altered by 
p110α knockdown, whereas sensitivity to treatment with 
ZSTK474 was significantly (6-fold) reduced (Figure 4G). 
This implies that the ability of combined PI3K/mTOR 
inhibitors to degrade MYCN protein is not dependent on 
intact p110β function, and furthermore that maintenance 
of MYCN protein levels in these cells largely proceeds 
through mTOR-dependent mechanisms. 
Elimination of MYcN protein requires 
concurrent inhibition of mtOrc1 and mtOrc2
Although NVP-BEZ235 and Torin1, both ATP-
competitive and potent inhibitors of PI3K/mTOR and 
Figure 4: Role of the p110α-PI3K complex in MYCN stabilization. Knockdown of p110 alpha PI3K with siRNA does not 
modulate MYCN levels in Kelly MYCN-amplified cells. A. Kelly neuroblastoma cells were transiently transfected with 100nM non-
targeting (-Ve control) siRNA, or with 100nM of 2 single siRNA targeting P110α- PI3K. Cells were harvested 96 h post siRNA treatment 
and P110α- PI3K, AKTSER473 and MYCN protein levels were assessed via western blotting. B. Kelly neuroblastoma cells were stably 
transduced with control shRNA viral particles (Consh, left panel) or viral particles containing P110α- PI3K coding shRNA (Right panel) 
and PI3K-P110α, AKTSER473 and MYCN protein levels assessed via western blotting. C. Kelly neuroblastoma cells were stably transduced 
with control shRNA viral particles or viral particles containing P110α- PI3K coding shRNA and cell viability determined by SRB Kelly 
and Kelly CONSH shRNA neuroblastoma cell lines were used as controls. Values represent the averages of three independent assays. Error 
bars; standard deviation. D. Knockdown of p110α-PI3K does not affect MYCN destabilization induced by NVP-BEZ235 and Torin1. Kelly 
neuroblastoma cells were transiently transfected with P110 alpha PI3K targeting siRNA and at 3 h pre-harvest treated with NVP-BEZ235 
(500nM), Torin1(500nM) or ZSTK474 (2μM). Cells were harvested 96 h post siRNA treatment and P110α- PI3K, AKTSER473 and MYCN 
protein levels were assessed via western blotting. E. Western blot analysis of Kelly Consh and Kelly PI3K-P110α shRNA cell lines treated 
with NVP-BEZ235 for 3 h. F., G. GI50s as determined by trypan blue exclusion method in Kelly Consh and Kelly PI3K-P110α shRNA cell 
lines treated for 72 h with NVP-BEZ235 or ZSTK474. Mean GI50 and standard error from three independent assays are shown.
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mTORC1/mTORC2 respectively, most effectively targeted 
MYCN in our studies, incomplete (rapalogue) inhibitors 
of mTOR have been more commonly used in the clinical 
setting. To establish if incomplete inhibition of mTORC1 
alone could be effective in destabilizing MYCN we 
used rapamycin at a low concentration, known to block 
mTORC1 but not mTORC2 [60]. We were only able to 
observe MYCN degradation using rapamycin at 10-20µM, 
a concentration at which total blockade of both mTORC1 
(as measured by p4EBP1THR37/46) and mTORC2 (as 
measured by AKTSER473) occurs (Figure 5A). Similarly, the 
PI3K inhibitor ZSTK474 was only active against MYCN 
at high concentrations coinciding with inhibition of both 
mTORC1 (as measured by p4EBP1THR37/46 inhibition) and 
mTORC2 (as measured by AKTSER473 inhibition, Figure 
3A). Furthermore, transient suppression of mTOR using 
siRNAs to target mTORC1 (RAPTOR) or mTORC2 
(RICTOR) in Kelly cells partially reduced MYCN levels 
and targeting of mTOR kinase completely eliminated 
MYCN (Figure 5B, S2A-C), leading to rapid cell-
killing (Figure 5C). Taken together these data imply that 
mTOR kinase plays a prominent role in the maintenance 
of MYCN stability and that complete blockade of both 
mTORC1 and mTORC2 is required to efficiently stimulate 
degradation of MYCN.
The mTOR complex modulates GSK3β activity 
and regulates MYcN protein degradation
The beta isoform of glycogen synthase kinase 
(GSK3β) is a PI3K/mTOR pathway component and 
direct target of AKT that alters phosphorylation of 
MYC oncoproteins at the CPD. Phosphorylation of the 
CPD mediates complex formation between E3 ligases 
and MYC proteins, driving their degradation within the 
proteasome [61]. Activity of the mTORC2 (RICTOR/
mTOR) complex specifically stimulates AKTSER473 
phosphorylation [62]. High levels of mTORC2 activity 
lead to inactivation of GSK3β (preventing phosphorylation 
of MYCN and proteasomal degradation). In our hands, 
Figure 5: Role of mTOR and GSK3β in MYCN stabilization. Impact of mTOR, RAPTOR and RICTOR knockdown on Kelly 
neuroblastoma cell growth and MYCN degradation. A. Western blot analysis of AKTSER473, GSK3βSER9, 4EPB1THR37/46, RPS6SER240/244 and 
MYCN levels after rapamycin treatment. SHEP WT and SHEP T58/S62 neuroblastoma cells were treated for 3 h with DMSO (V), with 
DMSO and IGF1 (V+I) or with rapamycin. Total AKT, GSK3β, S6 and 4EPB1 antibodies were used as controls for each corresponding 
phospho-specific antibody and GAPDH was used as a loading control. B. Kelly neuroblastoma cells were transiently transfected with 75nM 
and 100nM of mTOR, RAPTOR, RICTOR or non-targeting (Ve) siRNA and mTOR, RAPTOR, RICTOR and MYCN levels examined 
by western blot. C. Cell viability was determined by SRB assay. D. GSK3β inhibition stabilizes MYCN. Kelly neuroblastoma cells were 
transiently transfected with either a non-targeting (-Ve) or GSK3β targeting siRNA and at 3 h pre-harvest treated with NVP-BEZ235 
(500nM) or Torin1 (500nM). Cells were harvested 96 h post siRNA treatment and GSK3β and MYCN protein levels assessed by western 
blot. E. Chemical inhibition of GSK3β in Kelly cells. Kelly cells were untreated (U), treated with DMSO (V), with DMSO and IGF1 
(V+I), with GSK3β inhibitor SB216763 (SB) or with the indicated concentration of NVP-BEZ235 or Torin1 in the presence of SB216763. 
GSK3βSER9, total GSK3β and MYCN protein levels were assessed by western blot. GAPDH was used as a loading control. See also Figure 
S2.
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the ability of PI3K/mTOR pathway inhibitors (including 
NVP-BEZ235 and Torin1) to efficiently target MYCN 
required intact GSK3β activity (Figures 2 and 3). To test 
this observation, we knocked-out GSK3β with siRNA. 
Suppression of GSK3β increased stable intracellular 
levels of MYCN (Figure S2D, E) and both genetic (Figure 
5D) and pharmacologic (Figure 5E) inhibition of GSK3β 
abrogated the ability of NVP-BEZ235, Torin1 (and other 
PI3K or mTOR inhibitors, data not shown) to degrade 
MYCN. These data establish that the mTOR complex, and 
mTORC2 in particular, plays a critical role in maintenance 
of cellular MYCN levels, requiring intact function of 
GSK3β, the activity of which appears to be rate-limiting 
for the ability of PI3K/mTOR inhibitors to stimulate 
MYCN degradation. 
In vivo inhibition of mtOr-kinase targets 
MYcN-driven tumors in animal models
A stringent test of whether MYCN destabilization is 
a viable therapeutic strategy for MYCN-driven cancers is 
to establish whether murine tumors genetically-engineered 
to overexpress MYCN, together with primary human 
neuroblastoma tissue amplified for MYCN, are targeted in 
vivo. We assessed whether ZSTK474 and NVP-BEZ235 
could inhibit tumor progression using a transgenic model 
of neuroblastoma (TH-MYCN), in which tumor formation 
Figure 6: PI3K/mTOR pathway inhibition restricts the growth of MYCN-driven transgenic tumors. Tumor-bearing 
animals transgenic for TH-MYCN were treated daily using oral gavage with 45mg/kg NVP-BEZ235 (n = 8), NVP-BEZ235 vehicle (n = 11), 
400mg/kg ZSTK474 (n = 11) or ZSTK474 vehicle (n = 8). A. Average weight (g) of resected tumors relative to vehicle for NVP-BEZ235 
(top panel) and ZSTK474 (lower panel). B. Kaplan-Meier 21 day survival curves for NVP-BEZ235 (top panel) or ZSTK474 (bottom 
panel). C. Representative T2-weighted MRI images and gross pathology of vehicle NVP-BEZ235 or ZSTK474 treated tumors at indicated 
times (arrow = tumor, K, kidney). D. Western blot analysis of tumors treated with NVP-BEZ235, ZSTK474 or respective vehicles. M1-
M6 indicates tumor samples from cohorts of 6 individual animals, treated with either NVP-BEZ235, ZSTK474 or their respective vehicle 
controls. E. Tumor pathology (Hematoxylin & Eosin) and immunochemical staining (cl. Casp. 3) for vehicle (left panels) and NVP-
BEZ235 treated (right panels) tumors. (White arrows = vascularization). See also Figure S3.
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is driven by tissue-specific overexpression of MYCN 
within murine neural crest [63]. Animals were treated for 
21 days with 45mg/kg/day NVP-BEZ235 or 400mg/kg 
ZSTK474 [59, 64]. Both treatments were well tolerated 
(Figure S3A-C). Intra-tumoral levels of NVP-BEZ235 
and ZSTK474 were verified by mass spectroscopy and the 
drugs were present in tumor tissue above concentrations 
required for inhibition of their respective targets (Figure 
S3D). Tumor mass response following necropsy (Figure 
6A) and extension of survival (Figure 6B) were assessed 
as trial endpoints, and tumor regression was monitored 
in vivo using serial magnetic resonance imaging (MRI) 
(Figure 6C). Importantly, NVP-BEZ235 induced complete 
responses (by RECIST criteria) in the majority of treated 
tumors, with volume and mass reduction >75% (Figure 
6A) translating to extension of survival (Figure 6B). 
Conversely, ZSTK474 lacked any anti-tumor activity 
(compare Figure 6A, 6B upper and lower panels) despite 
achieving intra-tumoral concentrations sufficient for 
inhibition of AKT phosphorylation (Figure 6D). In 
responding tumors, NVP-BEZ235 blocked both PI3K 
(AKTSER473/308) and mTOR signaling (RPS6SER240/244), 
resulting in almost complete elimination of MYCN protein 
(Figure 6D), and induction of apoptosis (cleavage of 
caspase 3) on immunoblot and by immunohistochemistry 
(Figure 6D, 6E). Interestingly, two mice in the NVP-
Figure 7: Schematic model of regulatory pathways involved in MYCN turnover. In neuronal precursor cells, MYCN is initially 
phosphorylated at serine 62 (S62) by cyclin-dependent kinase 1/CyclinB. This acts as a priming phosphorylation that permits binding of 
GSK3β, PIN1 and PP2A. Subsequently, active GSK3β phosphorylates MYCN at threonine 58 (T58), yielding doubly phosphorylated 
MYCN. In a MYCN driven cancer cell model, RTKs activate PI3K, and the downstream target AKT, localising it to the membrane 
and allowing phosphorylation and activation of AKT at threonine 308 (T308) by PDK1. Active AKT phosphorylates and inactivates 
GSK3β, blocking phosphorylation of MYCN therefore preventing proteasomal degradation. The mTORC1 complex (mTOR-raptor) also 
directly phosphorylates and inhibits PP2A, enabling the accumulation of S62 phosphorylated and active MYCN. In addition, the mTORC2 
complex (mTOR-RICTOR) phosphorylates and further activates AKT at serine 473 (S473). NVP-BEZ235 destabilizes MYCN by blocking 
activation of AKT (via inhibition of TORC1 and TORC2 complexes) and reactivating GSK3β, permitting phosphorylation of MYCN (T58) 
and initiating proteasomal degradation.
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BEZ235 treatment cohort experienced incomplete 
responses with partial tumor regression and progression, 
respectively (T2 and T4, Figure S3A, B), and in each 
case inhibition of PI3K (AKTSER473/308) and mTOR 
(RPS6SER240/244) was incomplete, with only partial reduction 
in MYCN levels (M2 and M4, Figure 6D). Consistent with 
the idea that complete blockade of mTOR is a requirement 
for therapeutic efficacy of PI3K/mTOR pathway inhibitors 
in the setting of MYCN-dependency, ZSTK474 exhibited 
little activity against mTOR signaling (RPS6SER240/244) and 
demonstrated no therapeutic benefit in this MYCN-driven 
model (Figure 6D). 
To further confirm the efficacy of NVP-BEZ235 
as a therapeutic for MYCN-amplified neuroblastoma in 
patients, we performed an in vivo preclinical trial using 
a primary xenograft model in which tumor tissue from 
a patient (SFNB-08) with high-grade, MYCN-amplified 
neuroblastoma was implanted orthotopically into the 
kidney capsule. Animals were treated with NVP-BEZ235 
or vehicle for 14 days at 45mg/kg. Measurement of both 
tumor volume and weight again showed a significant 
decrease in tumor burden in NVP-BEZ235-treated animals 
in comparison to vehicle (Figure S4A, B). Immunoblotting 
of tumor tissue confirmed that NVP-BEZ235 blocked 
PI3K (AKTSER473/308, GSK3βSER9) and mTOR signaling 
(RPS6SER240/244, 4EBP1THR37/46) coincident with down-
regulation of intra-tumoral MYCN protein (Figure S4C). 
In addition, Ki67 staining showed a significant reduction in 
cellular proliferation (Figure S4D). Taken together, these 
data illustrate the potency of the PI3K/mTOR inhibitor 
NVP-BEZ235 against two different MYCN-driven tumor 
models, establish that the mechanism of action relates to 
elimination of MYCN protein, and highlight the potential 
for treatment of MYCN-driven malignancies in children 
using clinically available inhibitors of mTOR. 
DIscUssION
Oncogenic expression of MYC proteins is common 
in adult cancers and also occurs in neuroblastoma [1, 
2], medulloblastoma [8], rhabdomyosarcoma [7] and 
retinoblastoma [9], four common pediatric solid tumors 
that together account for a major fraction of death from 
relapsed cancer in children. In these conditions, aberrant 
expression of MYCN is associated with high-risk disease, 
poor clinical prognosis and death due to metastatic relapse 
(reviewed in [4]). The prominent role of MYC proteins 
in oncogenesis, and the fact that MYCN expression is 
restricted to tumor tissue in several pediatric malignancies 
with poor outcome, implies that MYCN is likely to be 
an important therapeutic target, presenting a unique 
opportunity for targeted molecular therapeutic intervention 
in pediatric cancer [4]. 
That particular cancers can be addicted to oncogenic 
signaling changes induced by aberrant MYC expression 
is well-established through the use of oncogene-regulated 
mouse models [63, 65-75]. In this setting, repetitive 
genetic inactivation of MYC causes regression of several 
malignancies without evidence of acquired genetic 
resistance, and with reversible toxicity to normal organs 
[5, 76-79]. Collectively, these data underpin the rationale 
for direct pharmacologic inhibition of MYC, however in 
practice this has been difficult. Given the prominent role 
of MYCN in the genesis of aggressive pediatric tumors, 
we sought to identify existing therapeutics that could be 
useful to target MYCN indirectly, using neuroblastoma as 
a paradigm of a pediatric tumor that exhibits both clinical 
and experimental evidence of dependence and addiction to 
MYCN overexpression. 
MYC-family proteins are oncogenically stabilized 
by altered phosphorylation within an n-terminal conserved 
phosphodegron domain (CPD). Binding to the CPD is a 
function of the ubiquitin ligases (FBW7, HUWE1) and 
is required for initiation of proteasomal degradation. 
Phosphorylation of conserved T58 and S62 residues 
within the CPD is regulated by CDK1 (a MAPK target), 
and by the PI3K/AKT-regulated targets GSK3β and 
mTOR, respectively (Figure 7). Based on knowledge of 
this mechanism, individual compounds which modulate 
GSK3β and target MYCN have been reported [13, 37, 80]. 
However, a comprehensive understanding of how PI3K/
mTOR inhibitors target MYC proteins and a rationale for 
the selection of compounds likely to be clinically active 
against MYC-driven cancers is lacking. Given that pan-
PI3K, dual PI3K/mTOR and TORC1/2 kinase inhibitors 
are progressing through early pediatric clinical evaluation, 
it is important to clearly define the patient population 
most likely to benefit from treatment and to prioritize 
inhibitors for clinical trials [52, 81]. To date, none of these 
compounds have been ranked for their potential to inhibit 
MYC/MYCN in pediatric cancers, although several drugs 
(rapamycin and the later generation rapalogue inhibitors 
temsirolimus and ridaforolimus) have been evaluated in 
the setting of relapsed solid tumors without a hypothesis 
relating to MYC or MYCN expression. 
A practical cell-based approach to rank compounds 
with the ability to destabilize MYC protein would provide 
a valuable roadmap to prioritize drugs for early phase 
trials. We therefore designed a chemical-genetic screen 
using isogenic (SHEP neuroblastoma) cells varying in 
expression of wild-type or CPD-mutated, stabilized 
MYCN, and we assessed selective sensitivity to treatment 
with a library of 228 drugs or chemical probes [82, 83]. 
No statistically significant difference in proliferation 
rate was observed between SHEP cells expressing wild-
type or stabilized MYCN in this screen, excluding the 
possibility that selective sensitivity related to changes in 
basal proliferation rate. However, we cannot discount the 
possibility that additional mechanisms associated with 
MYCN overexpression, and unrelated to stabilization 
of MYCN protein, could account for drug sensitivity in 
this screen. For example, MYC protein overexpression 
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has been linked to defects in apoptosis [84], altered DNA 
damage repair responses [85], changes in chromosomal 
stability [86] and cell metabolism [87]. Many of these 
factors are the likely basis for previously described 
synthetic lethal relationships associated with MYCN 
expression. Nevertheless, we were able to identify several 
classes of small molecule inhibitor that selectively target 
cells expressing MYCN protein, and as proof-of-principle 
we characterized one class of compound that demonstrated 
considerable efficacy in two independent pre-clinical 
models of MYCN-driven neuroblastoma. We illustrate the 
feasibility of this mechanistic and translational approach 
in identifying regulators of MYCN stability, focusing 
on PI3K/mTOR and mTOR inhibitors as an effective 
class and mitigating the risk of off-target effects by 
using multiple inhibitors across the pathway, as well as 
siRNA silencing of pathway components. We focus on 
NVP-BEZ235 as an example of a selective PI3K/mTOR 
inhibitor that is able to suppress MYCN protein and induce 
growth-inhibitory effects in MYCN expressing cells, 
although several candidate inhibitors are now in clinical 
evaluation. From our data, the most effective inhibitors 
induce total blockade of both mTORC1 and mTORC2, 
which appear to regulate downstream processes that are 
key in controlling MYCN protein levels and cellular 
dependency on MYCN expression. 
The basis for the relationship between MYCN 
expression and sensitivity to mTOR inhibition is unclear, 
but several possibilities are likely. In order to tolerate 
oncogenic overexpression of MYC, cancer cells must 
undergo a major remodeling of metabolic and translational 
pathways˗ both of which are regulated by mTOR [87]. 
Indeed, MYC has previously been shown to be involved 
in a feed-forward loop involving the translation machinery 
component eIF4F that links transcription and translation, 
regulating cell growth and protein synthesis [88, 89]. 
Uncoupling of this feed-forward loop via perturbations 
in expression of key proteins including those under the 
control of mTOR (such as 4EBP1) is a likely mechanism 
that fuels cancer cell growth and cellular addiction to 
MYC expression [16, 89-91]. Finally, neuroblastomas 
with high levels of MYCN expression exhibit defined 
metabolic deficiencies in glucose metabolism (Warburg 
physiology) and are polyamine-dependent under hypoxic 
conditions [92, 93]. MYC directly interacts with HIF-1 
linking altered cellular metabolism to tumorigenesis by 
regulating genes involved in the biogenesis of ribosomes, 
mitochondria, and regulation of glucose and glutamine 
metabolism [94, 95]. 
Advances in medicinal chemistry have delivered 
potent small-molecules to clinical use that have the ability 
to achieve effective in vivo blockade of major oncogenic 
signaling pathways through either direct targeting of 
oncoproteins or through synthetic lethal relationships 
exposed by oncogene expression [83]. The availability 
of multiple clinical inhibitors that target pathways of 
high relevance to cancer treatment mandates thorough 
mechanistic prioritization. Here we show that within the 
class of available inhibitors of PI3K/mTOR pathway, 
compounds that selectively block mTORC1/mTORC2, 
such as the combined PI3K/mTOR inhibitor NVP-
BEZ235, efficiently target MYCN protein stability and 
cause in vivo regression of neuroblastoma, a MYCN-
driven pediatric tumor. Selective inhibitors of PI3K do 
not exhibit this activity. This has important implications 
for planned trials of these compounds in pediatric cancer, 
since multiple PI3K, mTOR and dually targeted PI3K/
mTOR drugs are already in active clinical evaluation. 
The success of pediatric trials utilizing these agents will 
depend as much on careful selection of the appropriate 
agent as on the target patient population likely to benefit 
from treatment. 
MAtErIALs AND MEtHODs
cell lines and reagents
Kelly, SH-SY5Y, SHEP, SK-N-SH, IMR32, SKN-
Be2C, IMR5 and SK-N-AS human neuroblastoma cell 
lines were obtained from the University of California 
at San Francisco Cell Culture Facility (San Francisco, 
CA) and from the American Type Culture Collection 
(Manassas, VA). Cells were grown in DMEM or RPMI 
containing 10% fetal bovine serum (PAA “Gold”). In 
specified experiments, cells were serum starved in 0.2% 
FCS for 6 h before analysis and treated with recombinant 
human insulin-like growth factor-1 (IGF-1; Sigma) at 
50ng/mL for 30 min before harvesting. NVP-BEZ235 
(Novartis), Torin1 (Nathaniel Gray), staurosporine (Alexis 
Biochemicals), ZSTK474 (Alexis Biochemicals), GSK3β 
inhibitor (Calbiochem), TGX221 (Selleck chemicals), 
PIK90 (Selleck chemicals) and Rapamycin (Selleck 
chemicals) were all prepared as a 10mM stock solution in 
100% DMSO. Working solutions were prepared freshly by 
dilution in 100% DMSO prior addition to the cell media 
at a final concentration of 0.1% DMSO. SHEP cells were 
stably transfected with constructs wild-type or mutant 
for MYCN and appropriate clones were screened and 
selected essentially as described previously [37]. Cells 
were regularly screened for Mycoplasma using a PCR-
based assay (VenorGem, Minerva Biolabs).
In vitro proliferation and inhibitor treatment
Cells were seeded in triplicate wells of 96-well flat 
bottom culture plates (3-6 × 103 per well) and allowed 
to attach for 24 h to ensure exponential growth at the 
time of treatment. Cells were then incubated for 72 h in 
the presence of increasing concentrations of indicated 
inhibitors. Cell viability and median-effect concentration 
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affecting growth (GI50) was determined using the SRB 
(Sulforhodamine B colorimetric assay) and GI50 values 
were derived as described previously [96]. Apoptosis was 
assessed by caspase cleavage. The activities of caspase-3 
and -7 were measured by luminescence detection using 
the Caspase-Glo® 3/7 assay kit (Promega, Inc.). The assay 
provides a luminogenic caspase-3/7 substrate in a reagent 
that when added to cells results in cell lysis, followed 
by caspase cleavage of the substrate and generation of a 
luminescent signal produced by luciferase. The assay was 
performed according to the manufacturer’s instructions. 
The mean difference was calculated using Student’s 
t-test. Values were standardized to the maximal effect of 
Staurosporine (2μM). 
Kinase inhibitor screen
 SHEP WT and SHEP T58/S62 were seeded in 384-
well plates for 48 hours before treatment with 40, 200 and 
1000nM of 228 kinase inhibitors and chemical probes for 
96 hours [82, 97-99]. Cell viability was determined using 
CellTiter-blue reagent (Promega, Inc.). The Z-factor was 
>0.5 for all plates analyzed. The data was plotted as a ratio 
of SHEP T58/S62:SHEP WT.
Immunoblotting
 Inhibitor-treated cells were lysed and suspended in 
non-denaturing lysis buffer (Cell Signaling Technology, 
Danvers, MA) containing 1x concentrate protease and 
phosphatase inhibitor cocktail tablets (Roche, Lewes, UK). 
Samples were transferred to polyvinylidene difluoride 
membranes, which were incubated in a blocking buffer 
(5% dried milk in TBS or 3% ECL advance blocking 
reagent) and probed with primary antibody in blocking 
buffer overnight at 4°C. Proteins were detected with HRP 
conjugated secondary antibody (DAKO) and visualized 
with enhanced chemiluminescence reagents (GE 
Healthcare). Antibodies used were as follows: Rabbit anti 
MYCN polyclonal antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA), mouse anti MYCN monoclonal antibody 
(Calbiochem, Merck KGaA, Darmstadt, Germany), rabbit 
anti-phospho MYCN (S54) polyclonal antibody (Bethyl 
Labs, Montgomery, TX), rabbit anti-phospho c-Myc (T58/
S62) polyclonal antibody (Cell Signaling Technologies, 
Danvers, MA), Rabbit and mouse antibodies specific 
for total and phosphorylated forms from CST: AKT 
(#2965, #9267, #4058, #9272, #9271, #4056), ribosomal 
protein S6 (#2317, #2211), P70S6K (#9204, #2708), 
4EBP1 (#9644, #9459), GSK3β (#9323, #9315), cleaved 
caspase-3 (#9664), Raptor (#2280), Rictor (#2114), 
mTOR (#2983) and GAPDH (#2118). Phosphorylation 
of AKTSER473, GSKSER9, RPS6SER240/244 and P70S6KSER421/424 
was also determined using an electrochemiluminescent 
immunoassay (MesoScale Discovery) as described 
previously [44].
transfection of Kelly neuroblastoma cells with 
sirNA
 MYCN, GSK3β, mTOR, RAPTOR or RICTOR 
single or SMARTpool siRNA (Dharmacon) and PI3K-
P110α single siRNA (Ambion) was introduced into the 
cells by complex formation with Lipofectamine 2000 lipid 
transfection reagent (Invitrogen) according to transfection 
recommendations of the manufacturer. Lentiviral 
packaging vectors pMD2.G (3µg), pMDLg/pRRE (5µg), 
pRSV-REV (2.5µg) (Addgene) and the MYCN shRNA 
vector (10µg, TRCN0000020696, Sigma-Aldrich, UK) or 
control shRNA vector (10µg, SHC002 Sigma-Aldrich), 
also in complex with lipofectamine, were transfected into 
the HEK293T packaging cell line seeded in T75cm2 tissue 
culture flasks. Twenty-four hours after transfection, the 
culture media were replaced by fresh media corresponding 
to the cell line being transduced. After another 24 h of 
incubation, the lentiviral particle containing media were 
clarified by centrifugation and passed through a Millex 
HV 0.45 μm PVDF filter (Millipore, Bedford, MA, USA). 
The viral titre was calculated using the HIV p24 ELISA 
(Cambridge Biosciences) and viral aliquots stored at 
-80oC. KELLY, SHEP WT and SHEP T58/S62 cells were 
transduced with lentivirus at a calculated multiplicity 
of infection (MOI) of 10 (assuming 50% packaging 
efficiency) in the presence of polybrene (4µg/ml). The 
following day the virus-containing media were replaced 
with normal growth media and 24 h later, knock down 
cells were selected using puromycin (5µg/ml continuous 
treatment for at least 1 week). 
In vivo transgenic experiments
Transgenic TH-MYCN animals with palpable tumors 
(40-80 days old) were randomized and treated with 45mg/
kg NVP-BEZ235, 400mg/kg ZSTK474, or vehicle. NVP-
BEZ235 and ZSTK474 were administered via oral gavage. 
To assess the pharmacokinetic and pharmacodynamic 
profiles of NVP-BEZ235, plasma and tumor samples 
were harvested at 1 hour and 6 hours following dosing. 
Mice were bled by cardiac puncture, and plasma samples 
were collected and frozen at −20°C until analysis. Tumors 
were dissected, divided into 3 approximately equal 
pieces, and snap frozen in liquid nitrogen until analysis. 
For pharmacodynamic studies, tumors were homogenized 
using T-PER buffer™ (Thermo Scientific), 1x concentrates 
protease and phosphatase inhibitor cocktail tablets (Roche, 
Lewes, UK). Protein content was measured using Bradford 
reagent and samples were analyzed using immunoblotting 
as described previously. MRI was performed on a 7T 
Bruker horizontal bore microimaging system (Bruker 
Instruments, Ettlingen, Germany) using a 3cm birdcage 
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coil. Anatomical T2-weighted coronal images were 
acquired from twenty contiguous 1mm thick slices 
through the mouse abdomen, from which tumor volumes 
were determined using segmentation from regions of 
interest drawn on each tumor-containing slice At necropsy, 
tumors were excised, measured, weighed, and snap frozen. 
Significance analysis was performed using the Student’s 
t test. Mice were monitored daily and tumor size was 
palpated and animal weight measured daily. Animals 
were treated in accordance with local and national animal 
welfare guidelines [100].  
In vivo orthotopic experiments
A human MYCN-amplified primary tumor 
designated SFNB-08 was obtained from a patient with 
high-grade neuroblastoma, previously treated with 
cyclophosphamide, topotecan, cisplatin, etoposide, 
doxorubicin, and vincristine. Tumor pieces (4mm3) were 
implanted into the kidney capsule of nude mice. After 
7 days, mice were treated with either vehicle PEG300 
control or NVP-BEZ235 (45mg/kg in PEG300) daily 
for 14 days. Tumors were collected on the last day of 
treatment, weight and volume (as measured by digital 
caliper) were recorded and tissues taken for histopathology 
and western blotting
Drug measurements
Concentrations of NVP-BEZ235 in biological 
samples were determined using liquid chromatography/ 
mass spectrometry (LC-MS). Drug was extracted using 
3-4 vol methanol containing 500ng/ml Olomoucin used 
as internal standard. Chromatography carried out on 
a Kinetics C18 column (5.0 cm × 2.1 mm ID, 2.6-μm 
particle size; Phenomenex) using a 1290 LC system with a 
gradient mobile phase of 0.1% formic acid/methanol at 0.6 
mL/min over 10 minutes. Detection was by LC-MS using 
a Agilent 6410triple quadropole in which the analyte was 
ionized by electrospray interface in positive mode (gas 
temperature 300 flow 12 l/min, nebulizer 40psi, capillary 
voltage 4000V.The following transition were monitored 
[M + H]+472.2 to 454.2 at 50V collision energy for NVP-
BEZ235and [M + H]+ 299.1 to 177.1 at 30V collision 
energy for Olomoucin. The assay was linear in the range 
of 10-5000 nM.
statistical analyses
We analyzed quantitative results either by one-
way analysis of variance (multiple groups) or t test (two 
groups). We carried out survival analysis using Kaplan-
Meier log-rank test. We considered a difference with P < 
0.05 (two-sided) statistically significant.
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